OUR VISION
We are building a leading biotech company, utilising the power of ultrasound to unlock targeted oncology treatments
EGM March 13, 2026
Oslo, 13 March 2026:
An Extraordinary Shareholders Meeting were held on March 13, 2026.
KEY FOCUS AREA
Focus on Oncology
We are united in the mission:
ACT against pancreatic cancer
Latest company news:
-
First patient dosed in Europe in ENACT trial
The first patient has been dosed in Europe in the Phase 2 ENACT trial. The recruitment takes place at three hospital sites in Europe, in addition to seven sites in the U.S. All sites are now active.
-
EXACT Therapeutics will host a global investor call regarding the ongoing warrants exercise program
In conjunction with the ongoing warrants exercise, the Company will host a global investor call (in English) on Wednesday, 11 Feb 2026 at 3 PM CET/9:00 AM EST
-
GE Healthcare and main investors announce exercise of warrants
On 5 February, EXACT Therapeutics could announce that GE Healthcare as well as the primary insider shareholders will exercise all their warrants
-
Positive initial safety read-out from the Phase 2 ENACT trial, triggering option to exercise warrants
Our pipeline
Our technology
The Key differentiation of ACT is:
PS101 is an investigational pro-drug which is activated with dual-frequency ultrasound directed at the tumor site.
PS101, a formulation of perfluorobutane microbubbles and perfluoromethylcyclopentane microdroplets, is injected intravenously and insonated over the tumor site using diagnostic high frequency ultrasound pulses, triggering expansion into transient Acustic Cluster Therapy bubbles (~22 μm) in the tumor vasculature. Subsequent low MI (mechanical index), low frequency ultrasound pulses applied for minutes induces oscillations of ACT bubbles, increasing vascular permeability and promoting transvascular and stromal penetration of drugs.
PS101 increases the uptake of co-administered drugs from blood vessels into the surrounding (cancer) tissue. With PS101, the drug can reach ~100 microns which is 10 layers of cells away from capillary.
Reproducible and significant uptake through targeted delivery into tumours and across the blood brain barrier (BBB) has been demonstrated. PS101 has been found to be well tolerated in a Phase 1 trial.